The FDA is allowing a Phase I/II multicenter clinical trial using retinal cells derived from stem cells (hESCs). Advanced Cell Technology, Inc., will use the cells to treat patients with Stargardt's Macular Dystrophy (SMD). That's the report in MedicalNewsToday.
No comments:
Post a Comment